Brief: Impel Neuropharma Announces Publication Of Pivotal Phase 3, Open-Label Stop 301 Study Of Inp104 (Trudhesa) For Treatment Of Acute Migraine In Journal Headache
09/08/2021 14:19
Aug 9 (Reuters) - Impel Neuropharma Inc IMPL.O :
* IMPEL NEUROPHARMA ANNOUNCES PUBLICATION OF PIVOTAL PHASE
3,
OPEN-LABEL STOP 301 STUDY OF INP104 (TRUDHESA™) FOR TREATMENT OF
ACUTE MIGRAINE IN JOURNAL HEADACHE
Source text for Eikon: ID:nGNX1YhKd3
Further company coverage: IMPL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IPI Legacy Liquidation Co
See all newsBrief: Impel Pharmaceuticals- On Dec 19, 2023, Co And Impel NeuroPharma Australia Commenced Voluntary Chapter 11 Proceedings
Brief: Impel Pharmaceuticals Says On Dec 1 Michael Kalb Gave Notice Of Resignation From Position As CFO With Last Day To Be December 31
U.S. STOCKS ON THE MOVE-iRobot Corp, Faraday Future, Fisker
U.S. STOCKS ON THE MOVE-iRobot Corp, Fisker Inc, International Seaways Inc
Brief: Impel Pharmaceuticals Receives Delisting Notice From Nasdaq